Opinion|Videos|March 17, 2025
Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Author(s)Wayne Kuang, MD, Matt T. Rosenberg, MD
Wayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
Advertisement
Episodes in this series
Notes:
0:00-9:35 Dual Diagnosis: OAB and BPH
9:36-13:10 Understanding Symptoms of OAB
13:11-17:25 Managing OAB
17:26-28:44 Treatment Options for OAB
28:45-35:08 Role of Primary Care Providers
35:09-41:37 Educational Outreach in OAB
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5